Join to View Full Profile
601 N Caroline St # 3142Baltimore, MD 21287
Phone+1 410-955-6500
Dr. Weihe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Baylor College of MedicineResidency, Radiology-Diagnostic, 2007 - 2011- Baylor College of MedicineClass of 2006
Certifications & Licensure
CA State Medical License 2015 - 2027
CO State Medical License 2024 - 2025
TX State Medical License 2008 - 2018
MD State Medical License 2010 - 2015
American Board of Radiology Diagnostic Radiology
Publications & Presentations
PubMed
- Long-term treatment of metastatic adenoid cystic carcinoma with sequential brachytherapy and stereotactic body radiotherapy.Allison Y Zhong, Sangwoo S Kim, Austin Hopper, Greg White, Sayuri Miyauchi
Radiation Oncology Journal. 2024-09-01 - 2 citationsCorrection: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman
Breast Cancer Research. 2024-03-13 - 3 citationsA phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman
Breast Cancer Research. 2024-02-26
Abstracts/Posters
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Elizabeth K Weihe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Elizabeth K Weihe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/elizabeth-weihe
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
